One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

What Makes hubXchange’s Roundtable Series Unique? Intimate, Senior-Level Roundtable Discussions: Engage with C-level ...

The US regulator has turned down J&J's marketing application for a subcutaneous (SC) formulation of EGFRxMET bispecific ...

Specifically, that could include a ban on spread pricing – when a PBM reimburses pharmacies one price for a medicine, but ...

The FDA has approved Neurocrine Bioscience's Crenessity for classic congenital adrenal hyperplasia (CAH), the first drug for ...

Recruiting for clinical trials is hard… and expensive. And a large component of that time involves people sifting through ...

Its rare disease pipeline includes sickle cell disease therapy etavopivat, currently in the phase 2/3 HIBISCUS trial due to ...

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to ...

In a time when pharmaceutical companies no longer have the economic luxury of decades-long development cycles, indication ...

Essentially, what Concr demonstrates is that training their algorithms on smaller, yet more diverse, data can lead to increased accuracy, due to the broader biological variability within that training ...

The analysis found that across all the 339 appraisals carried out for the new medicines, the median gain in quality-adjusted ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...